A Single-arm, Open, Phase II Clinical Study of SBRT, Chemotherapy, and Ivonescimab Neoadjuvant Therapy for Luminal-type Breast Cancer
Latest Information Update: 04 Dec 2024
At a glance
- Drugs Ivonescimab (Primary) ; Carboplatin; Cyclophosphamide; Doxorubicin; Paclitaxel
- Indications Breast cancer; HER2 negative breast cancer
- Focus Therapeutic Use
- 04 Dec 2024 Last checked against ClinicalTrials.gov: US National Institutes of Health
- 02 Dec 2024 Planned initiation date changed from 1 Sep 2024 to 28 Nov 2024.
- 02 Dec 2024 Status changed from not yet recruiting to recruiting.